Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy.
CONCLUSION: Both pembrolizumab and nivolumab exhibited tolerable cutaneous safety profiles in a variety of cancer patients undergoing anti-PD-1 therapy. Cutaneous AEs of anti-PD-1 therapy were not associated with antibody type, underlying malignancy, patient characteristics, or improved response. PMID: 31269545 [PubMed - in process]
Publication date: Available online 15 November 2019Source: Pharmacological ResearchAuthor(s): Hao Jia, Haixia Peng, Zhaoyuan HouAbstractThe LIM protein Ajuba contains an unstructured proline/glycine-rich preLIM region in the N terminus and conserved tandem LIM motifs in the C terminus. Additionally, Ajuba contains both nuclear export sequences (NES) and nuclear localization sequences (NLS), which enable Ajuba shuttle between the cytoplasm and the nucleus. Thus, Ajuba can act as a versatile scaffold participating in assembly of variety of protein complexes to execute multiple cellular functions including cell adhesion, moti...
Publication date: Available online 14 November 2019Source: Pharmacological ResearchAuthor(s): Mingxue Li, Dun Wang, Jianhua He, Lixia Chen, Hua LiAbstractB-cell lymphoma-extra large (Bcl-XL) is one of the anti-apoptotic proteins of the Bcl-2 family that is localized in the mitochondria. Bcl-XL is one of the key regulators of apoptosis that can also regulate other important cellular functions. Bcl-XL is overexpressed in many cancers, and its inhibitors have shown good therapeutic effects. Bcl-XL interacts with Beclin 1, a key factor regulating autophagy.Bcl-XL is essential for the survival of neurons and plays protective ro...
Authors: Leow K, Lynch MF, Lee J PMID: 31718228 [PubMed - as supplied by publisher]
A. Praveena*, S. Arthi and B. Sudarmathi
CONCLUSION: Overall, allergic diseases are inversely associated with the risk of cancers. PMID: 30895928 [PubMed - in process]
Author Affiliations open 1Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada 2Swiss Tropical and Public Health Institute, Basel, Switzerland 3University of Basel, Basel, Switzerland 4Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands 5MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK 6National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA 7University Medical Center Groningen, Gron...
Background: Nivolumab is a programmed cell death-1 receptor (PD-1) inhibitor approved by the U.S. Food and Drug Administration for the treatment of melanoma, non-small cell lung cancer, renal cancer, and classical Hodgkin lymphoma. For patients on immune checkpoint modulators such as PD-1 inhibitors, cutaneous immune-related adverse events (irAEs) are a significant concern. Dermatologic toxicities include pruritus, vitiligo, eczema, lichenoid eruptions and Stevens-Johnson syndrome. Vitiligo-like depigmentation has been well described in melanoma patients receiving treatment with PD-1 inhibitors.
ConclusionsEczema is associated with a greater risk for the development of lung cancer. Further studies with more comprehensive information on potential confounders are warranted.
Conclusions These results suggest that non-eczematous skin and subcutaneous diseases is associated with lung cancer, thus supporting the lung governing skin and hair theory of TCM.
CONCLUSION: A few of the alarm symptoms show a high PPV, whereas the PPV for some symptoms currently remains unknown. To improve the GPs' diagnostic judgment, a new algorithm for calculating the PPV for combinations of symptoms and risk factors seems promising. PMID: 26050833 [PubMed - in process]